Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this updated analysis, patients with a greater proportion of T-cells exhibiting a memory-like phenotype experienced greater CAR T-cell expansion and more durable responses.
Format: Microsoft PowerPoint (.ppt)
File Size: 425 KB
Released: December 11, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Related Content

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

On-demand webcast from an ASH 2022 satellite symposium on asparaginase for the treatment of AYA and adult acute lymphoblastic leukemia, from Clinical Care Options (CCO)

Daniel J. DeAngelo, MD, PhD
Program Director
Emily Curran, MD Kjeld Schmiegelow, MD, DMSci
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

Experts address audience questions from a live symposium on AML treatment strategies and future therapy directions, from Clinical Care Options (CCO)

Daniel Pollyea, MD, MS
Program Director
Courtney DiNardo, MD, MSCE Eytan M. Stein, MD
Released: January 24, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings